Sparian Biosciences Inc. has been awarded a $19.5 million, 5-year grant to fund development of SBS-226 from IND submission through phase I development. SBS-226 is a first-in-class dual μ-opioid ...
Contributor: From 2021 to 2024, a 40% Rise in Commercially Insured Patients with Opioid Use Disorder
An increase in opioid use disorder was found in those who had commercial insurance, with those aged 31 to 40 years having the highest percentage of opioid use disorder. The Opioid Tracker includes a ...
It’s no secret the opioid crisis remains a major public health concern in the United States. It was declared a public health emergency in 2017, and for multiple years following, nationwide overdose ...
Southeastern Ohio has been disproportionately affected by substance use disorders, such as opioid use disorder for decades.
Access to medications for opioid use disorder (OUD) in the pharmacy is internationally accepted; however, in the US, methadone treatment for OUD can only be provided by opioid treatment programs (OTPs ...
Opioid use disorder during pregnancy remains a critical yet under-addressed public health issue in the U.S., according to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results